This publication reviews challenges associated with the management of myelofibrosis and examines the current and future role of janus-associated kinase inhibitors in the evolving treatment landscape.
Current and Future Trends in Myelofibrosis: Cytopenias
Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.
Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5